Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00233636|
Recruitment Status : Withdrawn
First Posted : October 6, 2005
Last Update Posted : January 27, 2011
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Cancer Carcinoma, Squamous Cell||Drug: Iressa (Gefitinib) Procedure: Radiotherapy||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||28 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressa™) & Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head & Neck|
|Study Start Date :||July 2003|
- Tumour Response Rate, as complete response (CR) and partial response (PR) . Six months after Last Patient In.
- Time to progression, Overall survival, Duration of response. Six months after Last Patient In.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00233636
|Study Director:||AstraZeneca Italy Medical Director, MD||AstraZeneca|